Gabapentin Capsule
Product Images NDC 67296-2192

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 67296-2192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-500count (100mg 500count)

Label for Gabapentin Capsules, USP 100 mg by Camber Pharmaceuticals, Inc. The label includes storage instructions at 25°C with excursions permitted between 15° to 30°C, dispensing guidance, dosage information stating each capsule contains 100 mg of gabapentin, and a pharmacist's note about a medication guide. It also lists the package size as 500 capsules and provides a U.S. contact number. Manufactured for Camber Pharmaceuticals, Inc., with batch details and a barcode present.*

FDA Label Image

300mg-500count (300mg 500count)

Label for Gabapentin Capsules, USP 300 mg by Camber Pharmaceuticals, Inc. The label includes storage instructions, dispensing guidelines, dosage reference, and manufacturer details. The package contains 500 capsules. The label also shows the NDC 31722-149-05 and a barcode.*

FDA Label Image

400mg-500count (400mg 500count)

Label for Gabapentin Capsules, USP 400 mg, manufactured for Camber Pharmaceuticals, Inc. The label includes storage instructions at 25°C with permitted excursions, dispensing information, and a pharmacist note regarding the Medication Guide. The package contains 500 capsules and provides a U.S. contact phone number. The manufacturing site is by HETERO in India.*

FDA Label Image

Equation (Equation)

A formula representing creatinine clearance (CLCr) calculation based on age, weight, serum creatinine, and adjustment for female patients. This formula is often used in clinical contexts to estimate kidney function but is shown here without further clinical interpretation.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' compares mean pain scores over 8 weeks between placebo and gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes periods for 'Week Dose Titration' and 'Week Fixed Dose'.*

FDA Label Image

Fig 2 (Fig 2)

Line graph showing weekly mean pain scores over 7 weeks in a study population. The graph compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day during 3- and 4-week dose periods, with mean pain scores decreasing more in gabapentin groups than placebo over time.*

FDA Label Image

Fig 3 (Fig 3)

A bar graph illustrating the proportion of responders (patients with ≥50% reduction in pain score) at the endpoint for two controlled postherpetic neuralgia (PHN) studies. The graph compares placebo (PBO) and various gabapentin (GBP) doses, showing higher response rates with GBP doses 1800 mg, 2400 mg, and 3600 mg compared to placebo, with statistical significance indicated.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot showing responder rates in patients receiving gabapentin expressed as differences from placebo by daily dose and study. The x-axis represents daily dose in milligrams ranging from 600 to 1800 mg, and the y-axis shows the difference in responder rate percentage from 2% to 22%. Data points are distinguished by three studies labeled as STUDY a (black squares), STUDY b (gray squares), and STUDY c (white squares).*

FDA Label Image

Structure (Struct)

Chemical structure diagram depicting the molecular structure of gabapentin, the active ingredient in GABAPENTIN 100 mg capsules by Redpharm Drug. The illustration shows the cyclohexane ring with attached amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.